One of the main scientific activities of ISPOR Russia St. Petersburg Chapter in 2017 was to continue the monitoring of the reimbursement lists in Russia.
In Russia the cost-effectiveness threshold is not yet introduced into the procedure of reimbursement lists revision and is not used as the criteria of inclusion or exclusion of drugs as in many other countries.
Due to the fact that in 2016 the reimbursement lists were not yet revised, ISPOR Russia St. Petersburg Chapter researchers focused on the data of the last two revisions from 2014 and 2015. They took the health economic data from the dossiers of anti-cancer drugs with ATC codes L01 and L02 submitted during that period. For each health economic evaluation they analyzed number of LYG, progression-free LYG, QALYs; incremental cost per one LYG, progression-free LYG and QALY.
The main goal was to calculate the median ICER for anti-cancer drugs included and rejected from the reimbursement and then compare it with the CE threshold in Russia. The median cost of one LYG, progression-free LYG and one QALY gained showed to be higher comparing to the willingness to pay a threshold in Russia by 1,5%, 125% and 50%, consequently. ICER/LYG did not differ between the drugs included and rejected from the reimbursement, ICER/QALY was slightly even higher in the group of included drugs compared to the group of rejected ones. This analysis was published in the Russian journal and the data is open.
The conclusion drawn from the work is that in Russia the drugs entered into the reimbursement system during the last two revisions have ICER/LYG almost equal to the threshold. (Reported by ISPOR Russia St. Petersburg Chapter)
ISPOR Russia St. Petersburg Chapter under the leadership of Professor Alexey Kolbin, organized and developed a very successful meeting on March 14, 2013 in St. Petersburg about the prospects of the creation of the Regional Agency of health Technology Assessment (HTA) in the city of St. Petersburg.
All the speakers highlighted the imperative need and the objective reasons for the need of HTA in St. Petersburg in order to provide efficient evidence-based information about the effectiveness of health technologies, managers and decision-makers in the health system. As there are no such agencies created in Russia yet, though many have been working towards such a project, but the newly formed Regional Agency of HTA in St. Petersburg will become a pilot project for the whole country. The scientific and practical basis for the creation of HTA in Russia already exists, taking into consideration international methodological support. All the attendees of the meeting unanimously confirmed the need for the consolidation of all medical, scientific, and political forces with the Executive branch of St. Petersburg at the lead, for the implementation of this very important project not only for the city of St. Petersburg and its region, but for the whole country.
The meeting attended 31 of the prominent representatives of academia, physicians, society of clinical pharmacologists of St. Petersburg, etc. A special committee of 18 representatives has been elected to start working on the creation of the Regional Agency of HTA in St. Petersburg.
ISPOR welcomes and supports this great initiative of Russia St. Petersburg Chapter and its President, Professor Alexey Kolbin.
|President||Alexey Kolbin, MD, PhD|
|President-elect||Sergey Zyryanov, MD, PhD|
|Secretary/Treasurer||Alexey Kurylev, MD|
Contact InformationISPOR Russia St. Petersburg Regional Chapter Office